BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Saridaki Z, Georgoulias V, Souglakos J. Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. World J Gastroenterol 2010; 16(10): 1177-1187 [PMID: 20222160 DOI: 10.3748/wjg.v16.i10.1177]
URL: https://www.wjgnet.com/1007-9327/full/v16/i10/1177.htm
Number Citing Articles
1
Katharina Balschun, Jochen Haag, Ann-Kathrin Wenke, Witigo von Schönfels, Nicolas T. Schwarz, Christoph Röcken. KRAS, NRAS, PIK3CA Exon 20, and BRAF Genotypes in Synchronous and Metachronous Primary Colorectal CancersThe Journal of Molecular Diagnostics 2011; 13(4) doi: 10.1016/j.jmoldx.2011.03.002
2
Mohamed H. Elmahdi, Alaa S. Abd Elhamid, Heba A.I. Bayoumi. Kirsten rat sarcoma protein and hypoxia-inducible factor 1 alpha expression in colorectal cancer and its association with tumor clinicopathological featuresEgyptian Journal of Pathology 2026; 46(1) doi: 10.4103/egjp.egjp_2_26
3
Z Saridaki, X Saegart, V De Vriendt, D Hatzidaki, S Palmans, L De Smedt, G De Hertogh, S Tejpar. KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?British Journal of Cancer 2015; 113(6) doi: 10.1038/bjc.2015.307
4
Zi-Xu Yuan, Xiao-Yan Wang, Qi-Yuan Qin, De-Feng Chen, Qing-Hua Zhong, Lei Wang, Jian-Ping Wang, Todd W. Miller. The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-AnalysisPLoS ONE 2013; 8(6) doi: 10.1371/journal.pone.0065995
5
Joseph Ryan Polli, Ping Chen, Brandon M. Bordeau, Joseph P. Balthasar. Targeted Delivery of Endosomal Escape Peptides to Enhance Immunotoxin Potency and Anti-cancer EfficacyThe AAPS Journal 2022; 24(3) doi: 10.1208/s12248-022-00698-x
6
Christine L. H. Snozek. Pharmacogenomics in Clinical Therapeutics2012;  doi: 10.1002/9781119959601.ch4
7
Zenia Saridaki, Natalia Asimakopoulou, Ioannis Boukovinas, John Souglakos. How to Identify the Right Patients for the Right Treatment in Metastatic Colorectal Cancer (mCRC)Current Colorectal Cancer Reports 2015; 11(4) doi: 10.1007/s11888-015-0270-9
8
Seyed Mohammad Hosseini, Javad Mohammadnejad, Hassan Yousefnia, Behrouz Alirezapour, Ali Hossein Rezayan. Development of 177Lu-Cetuximab-PAMAM dendrimeric nanosystem: a novel theranostic radioimmunoconjugateJournal of Cancer Research and Clinical Oncology 2023; 149(10) doi: 10.1007/s00432-023-04724-z
9
Balázs Szabó, Györgyi A. Nelhűbel, Adél Kárpáti, István Kenessey, Balázs Jóri, Csilla Székely, István Peták, Gábor Lotz, Zita Hegedűs, Balázs Hegedűs, Tibor Füle, Balázs Döme, József Tímár, József Tóvári. Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomasOral Oncology 2011; 47(6) doi: 10.1016/j.oraloncology.2011.03.020
10
Petra Schroeder, Carsten Lindemann, Kirsten Dettmar, Jürgen Brieger, Jan Gosepath, Benjamin Pogorzelski, Diane Seimetz, Judith Atz. Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatmentClinical and Translational Oncology 2011; 13(12) doi: 10.1007/s12094-011-0751-5
11
Andrew Hendifar, Carlyn-Rose Tan, Anand Annamalai, Richard Tuli. Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancerExpert Review of Anticancer Therapy 2014; 14(9) doi: 10.1586/14737140.2014.922881
12
Zacharenia Saridaki, Maria Tzardi, Chara Papadaki, Maria Sfakianaki, Fraga Pega, Aristea Kalikaki, Eleftheria Tsakalaki, Maria Trypaki, Ippokratis Messaritakis, Efstathios Stathopoulos, Dimitris Mavroudis, Vassilis Georgoulias, John Souglakos, Meenhard Herlyn. Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer PatientsPLoS ONE 2011; 6(1) doi: 10.1371/journal.pone.0015980
13
Jason A. Wilken, Andre T. Baron, Nita J. Maihle. The epidermal growth factor receptor conundrumCancer 2011; 117(11) doi: 10.1002/cncr.25805
14
Anja Pickhard, Simone Gröber, Anna Katharina Haug, Guido Piontek, Markus Wirth, Ulrich Straßen, Martina Rudelius, Rudolf Reiter. Survivin and pAkt as potential prognostic markers in squamous cell carcinoma of the head and neckOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 2014; 117(6) doi: 10.1016/j.oooo.2014.02.005
15
Annett Mueller, Erika Bachmann, Monika Linnig, Katrin Khillimberger, Carl Christoph Schimanski, Peter R. Galle, Markus Moehler. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell linesCancer Chemotherapy and Pharmacology 2012; 69(6) doi: 10.1007/s00280-012-1869-z
16
Xuejun Fan, Randall J Brezski, Ming Fa, Hui Deng, Allison Oberholtzer, Anneliese Gonzalez, William P Dubinsky, William R Strohl, Robert E Jordan, Ningyan Zhang, Zhiqiang An. A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacyBreast Cancer Research 2012; 14(4) doi: 10.1186/bcr3240
17
Tarik Ghadban, Judith L. Dibbern, Matthias Reeh, Jameel T. Miro, Tung Y. Tsui, Ulrich Wellner, Jakob R. Izbicki, Cenap Güngör, Yogesh K. Vashist. HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancerApoptosis 2017; 22(3) doi: 10.1007/s10495-016-1332-4
18
Slah Ouerhani, Karim Bougatef, Ismail Soltani, Amel Ben Ammar Elgaaied, Salem Abbes, Samia Menif. The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancerMolecular Biology Reports 2013; 40(6) doi: 10.1007/s11033-013-2512-8
19
Yan-Jun Qu, Qian-Shi Zhang, Bo Wang, Feng Zhang, Evenki Pan, Chun-Yan Zhao, Si-Ye Liu, Li-Ping Fang. Comprehensive next-generation sequencing reveals double primary colorectal carcinoma missed by diagnostic imaging: A case reportWorld Journal of Gastrointestinal Oncology 2023; 15(10): 1823-1828 doi: 10.4251/wjgo.v15.i10.1823